Fate Therapeutics (FATE) Peer Comparison

$2.47

$0.05 (1.86%)

As on 04-Sep-2026 13:37EDT

Market cap

$291 Mln

Revenue (TTM)

$6 Mln

P/E Ratio

--

P/B Ratio

2

Div. Yield

0 %

Edit

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	291	16,765	16,261	13,492	12,332
Revenue ($ Mln)	6	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-126.00	491.50	755.85	860.62	-325.10
Net Margin (%)	-1,941.09	17.67	71.69	35.33	-25.32
RoE (%)	-69.88	110.09	--	42.98	-57.72
Price to Earnings	--	35.25	19.00	17.40	--
Price-To-Book	1.98	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	6.49	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	31.82	1,982.07	103.47	85.67	109.42
Gross Profit	-6.26	760.62	588.53	2,236.43	902.26
Operating Expenses	111.33	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-133.59	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-126.00	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-126.00	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	153.44	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	74.07	187.89	384.48	288.55	346.72
Current Liabilities	32.59	1,435.43	464.70	361.93	374.20
Total Liabilities	318.94	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	102.15	1,006.90	895.24	1,243.41	45.47
Current Assets	157.95	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	318.94	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	75.68	120.10	449.89	165.93	347.75
Net Current Assets	0.00	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-106.08	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	111.17	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	5.49	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-39.57	53.56	-30.01	32.82	-31.49
ROE (%)	-69.88	110.09	163.18	42.98	-57.72
ROA (%)	-30.79	15.64	26.53	29.32	-22.97
EBIT Margin (%)	-1,476.46	21.13	5.73	31.04	-18.97
Net Margin (%)	-1,941.09	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-23.36	24.67	114.85	9.23	149.04
EBIT Growth (%)	42.40	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	26.54	17.50	378.76	42.89	-15.32
EPS Growth (%)	27.45	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-42.20	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-0.86	36.06	-59.76	15.79	-45.32
Price / Book Value	0.56	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.07	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.03	0.00	0.05	0.00	0.00
Current Ratio	4.85	0.73	2.99	3.46	3.20
Quick Ratio	4.85	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-19.80

Operating Efficiency Ratios

	Fate Therapeutics (FATE)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	10.83	15.88	21.25	13.74	14.98
Asset Turnover	0.02	0.89	0.37	0.83	0.91
Receivable days	122.42	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	170.17	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly